Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06617091 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.

Study acronym: IAVI C114
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 3 sitesv3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 7 more changesShow less
    • Start date changed from estimate of Feb 12, 2025 to Jul 28, 2025
    • Primary endpoints: 1 to 3
    • Study sites: 0 to 3
    • Primary and study completion dates: Dec 30, 2026 to Mar 31, 2027
    • Eligibility criteria shortened, about 208 words
    • Secondary endpoints: 1 to 7
    • Study title shortened, about 2 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 1 Randomized Double Blinded Placebo Controlled, Dose Ranging Trial, of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine (GRAdHIVNE1 Vaccine), Administered to Healthy Adults Living without HIV and Living with HIV, in Southern Africa
Trial Details
NCT Number NCT06617091
Lead Sponsor International AIDS Vaccine Initiative
Collaborators: Ragon Institute, ReiThera Srl, Mutala Trust
Conditions
(from sponsor)		 HIV
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov